Zevra Therapeutics, Inc. Stock Issued During Period, Value, Issued for Services
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Zevra Therapeutics, Inc. stock issued during period, value, issued for services for the quarter ending 2025-03-31 was $75.00K, a 33.93% increase year-over-year.
- Zevra Therapeutics, Inc. stock issued during period, value, issued for services for the quarter ending 2024-09-30 was $150.00K, a 111.27% increase year-over-year.
- Zevra Therapeutics, Inc. stock issued during period, value, issued for services for the quarter ending 2024-06-30 was $193.00K, a 672.00% increase year-over-year.
- Zevra Therapeutics, Inc. stock issued during period, value, issued for services for the quarter ending 2024-03-31 was $56.00K, a 33.33% increase year-over-year.
- Zevra Therapeutics, Inc. stock issued during period, value, issued for services for fiscal 2025 was $75.00K, a 84.18% decline from fiscal 2024.
- Zevra Therapeutics, Inc. stock issued during period, value, issued for services for fiscal 2024 was $474.00K, a 108.81% increase from fiscal 2023.
- Zevra Therapeutics, Inc. stock issued during period, value, issued for services for fiscal 2023 was $227.00K, a 1.34% increase from fiscal 2022.
- Zevra Therapeutics, Inc. stock issued during period, value, issued for services for fiscal 2022 was $224.00K, a 25.83% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Issued for Services 3 month | Stock Issued During Period, Value, Issued for Services 12 month |
|---|---|---|
| 2025-12-31 | $75.00K 10-K · filed 2026-03-09 | |
| 2025-03-31 | $75.00K 10-Q · filed 2026-08-05 | |
| 2024-12-31 | $474.00K 10-K · filed 2026-03-09 | |
| 2024-09-30 | $150.00K 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $193.00K 10-Q · filed 2025-11-05 | |
| 2024-03-31 | $56.00K 10-Q · filed 2025-11-05 | |
| 2023-12-31 | $227.00K 10-K · filed 2025-03-12 | |
| 2023-09-30 | $71.00K 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $25.00K 10-Q · filed 2024-11-13 | |
| 2023-03-31 | $42.00K 10-Q · filed 2024-11-13 | |
| 2022-12-31 | $224.00K 10-K · filed 2024-04-01 | |
| 2022-09-30 | $65.00K 10-K · filed 2024-04-01 | |
| 2022-06-30 | $50.00K 10-K · filed 2024-04-01 | |
| 2022-03-31 | $50.00K 10-K · filed 2024-04-01 | |
| 2021-12-31 | $302.00K 10-K · filed 2023-03-07 | |
| 2021-09-30 | $73.00K 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $72.00K 10-Q · filed 2022-11-10 | |
| 2021-03-31 | $82.00K 10-Q · filed 2022-11-10 | |
| 2020-12-31 | $202.00K 10-K · filed 2022-03-31 | |
| 2020-09-30 | $47.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $84.00K 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |